Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

802.83 -16.55 (-2.02%)
Official Closing Price Updated: 7:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
99 100 Next >
Viking's 42% Plunge Splits Experts—A '$129 Strong Buy' Or 'Clearly Inferior' Drug?
Viking (VKTX) stock plunged 42% after its obesity pill trial. Experts are split: some call it a $129 Strong Buy, others say it's inferior. 
Via Benzinga
Viking Therapeutics Plummets as Oral Obesity Drug Trial Raises Tolerability Concerns
San Diego, CA – Viking Therapeutics (NASDAQ: VKTX) experienced a dramatic stock decline today following the release of disappointing clinical trial results for its highly anticipated oral tablet... 
Via MarketMinute
Viking Obesity Pill Faces Steep Climb Against Lilly's Tirzepatide, Analyst Calls Downtrend Reaction 'Extreme'
Viking shares fell on Phase 2 obesity pill data as tolerability issues surfaced, but William Blair says the stock's sell-off is excessive. 
Via Benzinga
Buy, Sell, or Hold? Insiders Pile Into These 3 Healthcare Stocks
Insiders are buying stocks like LLY, TFX, and CALC. The question is whether they are also a good buy for investors, and not all of them are. 
Via MarketBeat
This Drugmaker Stock Slumped 36% In Tuesday’s Premarket Session: Here’s Why
Via Stocktwits
A Look Into Eli Lilly Inc's Price Over Earnings
 
Via Benzinga
Why Novo Nordisk Stock Popped Today
For a cheap GLP-1 weight loss stock like Novo Nordisk, almost any news can help the stock pop. 
Via The Motley Fool
Why Viking Therapeutics Stock Crashed Today
Viking's new GLP-1 weight loss pill is pretty great -- but is it enough to turn the company profitable? 
Via The Motley Fool
Eli Lilly Stock Investors Need to See This
Competition among the makers of weight loss treatments is intensifying. 
Via The Motley Fool
Like Eli Lilly, Viking Therapeutics' Oral Weight Loss Drug Disappoints, Stock Tanks
Viking Therapeutics reported positive Phase 2 results for VK2735, showing significant weight loss and safety in obesity patients versus placebo. 
Via Benzinga
Viking Therapeutics Crashes 35% On Mixed Results For Its Weight-Loss Pill
Shares lost more than a third of their value after Viking unveiled mixed results for its oral VK2735. 
Via Investor's Business Daily
3 Undervalued Healthcare Stocks You Can Buy Now and Hold Long-Term
The healthcare industry is one of the laggards of 2025. 
Via The Motley Fool
Stock Market Today: S&P 500 Slips, Dow Futures Rise—Intel, Palo Alto, Home Depot In Focus
U.S. stock futures were fluctuating on Tuesday following mostly unchanged moves from Monday. Futures of major benchmark indices were mixed. 
Via Benzinga
Topics Stocks
Eli Lilly Considering Viking Therapeutics Acquisition? Expert Says 'They're Setting Up For Something BIG' As LLY Issues 40-Year Bond
Eli Lilly's rare 40-year bond sparks talk of a Viking Therapeutics (VKTX) acquisition. Experts say LLY is "setting up for something BIG." 
Via Benzinga
Topics Bonds
GoodRx Holdings Surges 5% After Hours on Novo Nordisk Partnership for $499 Monthly Ozempic, Wegovy Access
GoodRx stock rose 5.08% after it partnered with Novo Nordisk to offer Ozempic and Wegovy at a flat $499 monthly price for self-paying patients. 
Via Benzinga
Ozempic And Wegovy Now Available Through GoodRx At Reduced Self-Pay Price, Stock Skyrockets
GoodRx and Novo Nordisk launch a $499 monthly self-pay option for Ozempic and Wegovy, expanding access at 70,000 pharmacies across the U.S. 
Via Benzinga
Why Novo Nordisk Stock Popped Monday
Novo Nordisk stock looks so cheap, any good news at all can make it pop. 
Via The Motley Fool
Profusa Inc (NASDAQ: PFSA) Establishes a distributor partner in Spain for Lumee Oxygen platform
Via AB Newswire
1 Stock Down 40% This Year to Buy and Hold
This might be a wonderful entry point for long-term investors. 
Via The Motley Fool
The Best Growth Stock ETF to Invest $100 in Right Now
This ETF has outperformed the S&P 500 handily over various multi-year periods. 
Via The Motley Fool
Topics ETFs Stocks
1 Beaten-Down Stock That Could Soar by the End of the Year
The drugmaker has a major catalyst on the way. 
Via The Motley Fool
This Healthcare Stock's Bad News Could Create a $10 Billion Opportunity for Competitors
The drugmaker's recent dip could also be a buying opportunity. 
Via The Motley Fool
3 Fantastic Growth Stocks to Buy in August
Only one of these growth stocks is up big so far in 2025. But all three could be huge winners over the next few years. 
Via The Motley Fool
Jim Cramer Says Don't Quit Market When It's Frothy: 'Is Widespread Irrationality a Reason To Sell Down in Perfectly Rational Stocks? Absolutely Not'
In the face of a frothy market, Jim Cramer encourages investors to stay the course, highlighting numerous positive stock narratives that counterbalance the market's irrationality. 
Via Benzinga
Is Eli Lilly Stock a Buy? Here's What the Market Isn't Pricing in Yet.
Viking Therapeutics' dual-formulation obesity drug could be the David to Lilly's Goliath. 
Via The Motley Fool
Topics Economy
This Red-Hot Vanguard ETF Just Hit an All-Time High. Here's Why It's Still Worth Buying in August.
The Vanguard Dividend Appreciation ETF has an excellent balance of growth, income, and value stocks. 
Via The Motley Fool
Topics ETFs
Why Novo Nordisk Flew Almost 3% Higher on Friday
It seems to be holding off on price adjustments demanded by President Trump. 
Via The Motley Fool
Topics Government
Why Eli Lilly (LLY) Stock Is Up Today
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.2% in the afternoon session after the stock extended its positive momentum partly fueled by reports of major insider buying by top... 
Via StockStory
Topics Artificial Intelligence
Novo Nordisk's Lead Fades, Eli Lilly Holds Course For Outsized Gains, Says Analyst
Eli Lilly's pricing strategy for GLP-1 drugs is expected to have minimal margin impact, with BofA reaffirming a $900 price target. 
Via Benzinga
UnitedHealth's Best Day Since 2008, Intel's Best Weekly Gain In Decades: What's Moving Markets Friday?
Major tech-heavy indices edged lower from record highs by midday Friday in New York, as investors adopted a cautious stance ahead of the Trump-Putin meeting and after data showed a dip in consumer... 
Via Benzinga
Topics Economy
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.